Loading the company…
Loading the company…
In the last ten years FDA made 9 decisions for Insulet (510(k) clearances, De Novo grants, PMA approvals and supplements) under the product codes MedaRep maps to 1 procedure family, the most in 2019 (3). The latest was on 2023-10-18.
| Family | Decisions on record |
|---|---|
| CGM & insulin pump management | 16 |
In 2025, Insulet reported engagement with 7,998 surgeons and other clinicians in the states MedaRep covers, worth $2.9M in consulting, speaking, meals and travel for its device products, the most in Texas ($465K to 694). Royalties are left out.
| Omnipod Insulin Management System, Omnipod DASH Insulin Management System |
Decisions under the product codes mapped to the procedure families; devices filed under other codes are not here. Applicants are rolled up to Insulet.
Spend tied to a procedure counts the payments whose product names it. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing.Top states by spend: Texas ($465K, 694 engaged), Florida ($347K, 627 engaged), Maryland ($207K, 144 engaged), New York ($185K, 672 engaged), California ($150K, 497 engaged).